"Drug Resistance, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation.
| Descriptor ID |
D024882
|
| MeSH Number(s) |
G06.225.420 G06.920.225 G07.690.773.984.269.420
|
| Concept/Terms |
Drug Resistance, Viral- Drug Resistance, Viral
- Drug Resistances, Viral
- Antiviral Drug Resistance
- Antiviral Drug Resistances
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Viral".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Viral".
This graph shows the total number of publications written about "Drug Resistance, Viral" by people in this website by year, and whether "Drug Resistance, Viral" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 2 | 4 | 6 |
| 2002 | 11 | 11 | 22 |
| 2003 | 15 | 11 | 26 |
| 2004 | 18 | 16 | 34 |
| 2005 | 9 | 14 | 23 |
| 2006 | 18 | 18 | 36 |
| 2007 | 20 | 20 | 40 |
| 2008 | 18 | 20 | 38 |
| 2009 | 12 | 16 | 28 |
| 2010 | 22 | 19 | 41 |
| 2011 | 22 | 18 | 40 |
| 2012 | 16 | 17 | 33 |
| 2013 | 16 | 14 | 30 |
| 2014 | 17 | 13 | 30 |
| 2015 | 11 | 12 | 23 |
| 2016 | 12 | 12 | 24 |
| 2017 | 12 | 4 | 16 |
| 2018 | 9 | 8 | 17 |
| 2019 | 10 | 8 | 18 |
| 2020 | 7 | 14 | 21 |
| 2021 | 4 | 7 | 11 |
| 2022 | 1 | 5 | 6 |
| 2023 | 0 | 4 | 4 |
| 2024 | 3 | 11 | 14 |
Below are the most recent publications written about "Drug Resistance, Viral" by people in Profiles.
-
Identifying Allosteric Small-Molecule Binding Sites of Inactive NS2B-NS3 Proteases of Pathogenic Flaviviridae. Viruses. 2024 Dec 24; 17(1).
-
Real-World Comparison of Maribavir to Foscarnet for the Treatment of Cytomegalovirus in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. Viruses. 2024 Dec 07; 16(12).
-
Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies. Clin Infect Dis. 2024 Nov 22; 79(5):1197-1207.
-
Antiviral Susceptibility of Swine-Origin Influenza A Viruses Isolated from Humans, United States. Emerg Infect Dis. 2024 Nov; 30(11):2303-2312.
-
Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum. Clin Infect Dis. 2024 Sep 26; 79(3):787-794.
-
A drug repurposing screen identifies decitabine as an HSV-1 antiviral. Microbiol Spectr. 2024 Nov 05; 12(11):e0175424.
-
Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2. J Infect Dis. 2024 Aug 16; 230(2):394-402.
-
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial. Lancet HIV. 2024 Aug; 11(8):e508-e521.
-
Maternal Syphilis Leading to High Efficiency In Utero Transmission of Antiretroviral Resistant HIV: Intersection of Two Pandemics. Pediatr Infect Dis J. 2024 Oct 01; 43(10):977-979.
-
Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody. PLoS Pathog. 2024 Apr; 20(4):e1011680.